From navigating jurisdictional variations in patent eligible subject matter to regulatory and patent extension regimes, organisations in this sector need IP advisors who understand not only the science, but the commercial, regulatory and clinical realities that shape success.
Health, pharmaceutical, biopharmaceutical and medTech organisations form the largest segment of our client base. We work with scientific and industrial research organisations, universities, start-ups, small-medium and large entities, multinational companies, and international IP firms seeking trusted local expertise.
We have worked to protect innovations and advancements in drug discovery, formulations, drug delivery, vaccines, methods of treatment and manufacture and device-based technologies. We have a strong understanding of global patent and regulatory exclusivities (including data and market exclusivities) and have facilitated entry of several health-related, pharmaceuticals/biopharmaceuticals, and medical devices to market.
We provide clear end-to-end IP support to this sector, including patentability and freedom to operate searches, patent drafting and prosecution in Australia and overseas, patent term extension, design registration, product launch support, oppositions and enforcement of rights, and drafting, reviewing and negotiating key commercial agreements. Where required, our sector experts collaborate with our litigation group on patent infringement and validity matters.
We have helped protect some of the most innovative breakthroughs in modern medicine, from mRNA vaccines and CRISPR-Cas technologies to personalised medicine platforms, and CAR-T cell therapies.
Beyond securing rights, managing portfolios, and acting in contentious matters such as oppositions and infringement and validity proceedings, we also advise clients in relation to the commercialisation of their technologies. This includes drafting, reviewing and negotiating key commercial agreements such as early-stage confidentiality protocols, R&D agreements, funding agreements, as well as licensing and royalty arrangements. Through our extensive network, we also help clients navigate the funding, regulatory, marketing, and product-development pathways required to bring health innovations to market.
Most of our professionals have more than a decade of experience in research or industry, including in-house roles within academic institutes, research organisations, and ASX-listed or multinational companies. Many have post-doctoral expertise in fields such as immunology, oncology, biotechnology, biotechemistry, organic and medicinal chemistry, materials science, molecular and cell biology – allowing us to quickly understand complex innovations and provide practical, commercially relevant advice.
Our clients tell us they value our curiosity, scientific technical depth, ability to appoint the right attorney at the right time, and understanding of commercial drivers, as well as our pragmatic, solutions-focused approach.
Our team remains actively engaged with the sector through involvement in organisations such as AusBiotech, AusMedtech, Convergence Science Network, BioMelbourne Network, RACI, Small Technologies Cluster and the South Australian Medical Device Partnering Program. This engagement ensures we remain ahead of sector developments, regulatory changes, and emerging opportunities.
In a highly regulated sector with long development timelines, we help clients anticipate risk, support investment, and progress innovations from concept to market.
